Royalty Pharma’s Acquisition of Additional Royalty Interest Vertex Pharmaceuticals

Dechert advised Royalty Pharma plc on IP-related matters on the deal. Goodwin Procter LLP advised Royalty Pharma plc, while Mintz advised the Cystic Fibrosis Foundation on…

This content is for Standard 1 Year members only.
Login Join Now

Underscore VC’s $58 Million Fund III Closing

Vitro’s $100 Million Term Loan with ING

Milk & Honey’s Acquisition of VMG Sports

Soprema’s Acquisition of Polipox

Grupo Salta Educacao’s R$500 Million Real Estate Receivables Certificates Offering

ICC Inversiones’ Acquisition of 20,1% Stake in Grupo Patio SpA

Schroders Plc’s £250 Million Bond Issuance

Eleco’s Acquisition of Vertical Digital

Air IT’s Acquisition of SCS Technology Solutions

KOKO Networks Limited’s Financing Round

India Vehicle Finance’s Notes Offering

Al-Arafa’s Demerger into Concrete Fashion Group and GTEX

SC Ventures’ $100 Million Joint Venture With SBI Holdings

GreenCorp’s Acquisition of Emad Bakeries

MedOne’s Agreement with Shikun and Binui Energy

Sterlite Technologies’ Qualified Institutions Placement

Weihai City’s Bonds Offering

ScotPac’s Term Securitisation

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Hefesto Asesores continues to consolidate its position in the International Private Equity and Venture Capital market, with the formation of Hefesto Global

Paul Hastings Adds Premier Private Equity Buyout Team

The Distinctive Character Of The ‘Vespa’ Is No Longer In Question

Cultural Heritage Sites With Restrictions On Intended Use: The Council of State Acknowledges That This Power Lies In the Hands Of The Ministry Of Culture

The Italian Revenue Agency Qualifies Directors’ Reversible Remuneration For The Purposes Of Double Taxation Agrements.

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Paul Hastings Adds Premier Private Equity Buyout Team

BCLP Appoints Trevor Varnes as Chief Financial Officer

Royalty Pharma’s Acquisition of Additional Royalty Interest Vertex Pharmaceuticals

Author: Ambrogio Visconti